Document is current
Any future updates will be listed below
-
Authors
Hou, Xiaonan
Zanfagnin, Valentina
Xu, Conway
Jessen, Erik
Liu, Yuanhang
Wang, Chen
Huang, Yajue
Fontaine, Shaun D.
Santi, Daniel V.
Colon-Otero, Gerardo
Gill, Sarah E.
Glaser, Gretchen E.
Butler, Kristina A.
Bakkum-Gamez, Jamie N.
Dowdy, Sean C.
Oberg, Ann L.
Larson, Melissa C.
Atkinson, Hunter J.
Duffield, Laura N.
Peterson, Kevin L.
Kaufmann, Scott H.
Weroha, S. John
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA015083)
Novartis Pharmaceuticals Corporation (Support for development of two PDX models)
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 2 May 2025
First Online: 19 May 2025
Declarations
:
: Under the aegis of protocols approved by the Mayo Clinic Institutional Review Board (IRB), all patients gave written consent to participate prior to primary surgery or clinical biopsy for recurrent disease (#09-008768, #15-007262, or #17-007946). All of the animal studies were approved by the Mayo Clinic Animal Care and Use Committee in facilities that are accredited by the American Association of Laboratory Animal Care.
: All authors read and approved the final manuscript.
: Shaun Fontaine and Daniel Santi disclose options/shares in Prolynx stocks. Gerardo Colon-Otero discloses research support to Mayo Clinic from Seagen and Repare. Jamie Bakkum-Gamez discloses inventor of Mayo Clinic intellectual property which is licensed to Exact Sciences (Madison WI) and may receive royalties, paid to Mayo Clinic. All other authors declare no conflicts of interest.
